Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Assessing Johnson & Johnson (JNJ) Valuation After Autoimmune Pipeline Advances And New R&D Partnership
Johnson & Johnson (JNJ) has seen its share price climb following positive Phase 3 results for its oral psoriasis drug ICOTYDE and a significant R&D partnership with Royalty Pharma for JNJ-4804. Despite a 63% total shareholder return over twelve months, valuation models present conflicting views; Simply Wall St’s narrative suggests JNJ is 40% overvalued at $243.04 with a fair value of $174, while a discounted cash flow (DCF) model indicates it may be undervalued, trading below an estimated $363.77. Investors are encouraged to review both qualitative and quantitative factors to determine their stance on JNJ’s future prospects.